CareersInvestor RelationsPress CenterCOVID-19
  1. Home
  2. Medical Imaging
  3. Magnetic Resonance Imaging
  4. Options and Upgrades
  5. Clinical Software Applications
  6. syngo.MR OncoCare

syngo.MR OncoCare

Siemens - MRI - syngo.MR OncoCare - Image
syngo.MR OncoCare

Quantitative volumetric evaluation of functional response to treatment.

syngo.MR OncoCare1 is your new tool for advanced oncology reading, designed to positively address therapy benefit.

With its histogram analysis, back-mapping, and trending functionalities, syngo.MR OncoCare offers a solution for quantitative evaluation of functional lesion response to treatment. It has the potential to allow earlier assessment of treatment response, leading to treatment path optimization and savings of unnecessary treatment costs.

  • Features & Benefits
  • Clinical Use
  • General Requirements
Try

Features & Benefits

Features

As extension of the MR Oncology workflow, syngo.MR OncoCare1 provides rich feature sets for histogram analysis and trending over multiple time points:

  • VOI- and ROI-based histogram analysis
  • Intuitive color definition for three histogram domains
  • Savable presets for histogram analysis
  • Back-mapping of histogram colors on the image of reference
  • Export in .CSV format of pixel intensity values
  • Trending plot

 
Benefits

  • Quantitative assessment of the functional behavior of lesions for earlier assessment of therapy benefit
  • Improved communication towards referrers and oncologists with the back-mapping functionality
  • Additional research possibilities with the export functionality

Clinical Use

Examples for clinical application

Monitoring bone marrow metastases treatment

Histogram analysis of whole-body diffusion-weighted images and ADC maps has been documented to be a powerful tool to monitor response to treatment in skeletal therapy.

Earlier assessment of response to TACE therapy

Volumetric functional MR assessment is documented to predict TACE therapy response after one month2, where the currently available imaging criteria (morphology-based) assess therapy response after six months, earliest3.

The benefits are two-fold: Treatment path optimization and savings of unnecessary treatment costs.

General Requirements

System

  • MAGNETOM Vida
  • MAGNETOM Amira
  • MAGNETOM Sempra
  • MAGNETOM Solafit
  • MAGNETOM Vidafit
  • MAGNETOM Sola
  • MAGNETOM Altea
  • MAGNETOM Lumina

Minimum Software Version

syngo.via VB10
syngo.MR Onco

Other

Please Note: Additional technical pre-requisites may apply. Upon receiving your request, your local Siemens representative will clarify whether your system meets the requirements.

1syngo.via VB10 and the syngo.via based software options are currently under development; not for sale in the U.S. and other countries. Future availability cannot be guaranteed.

2

Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy Radiology. 2013;268:431-9

3

Hepatocellular Carcinoma: Response to TACE Assessed with Semiautomated Volumetric and Functional Analysis of Diffusion-weighted and Contrast-enhanced MR Imaging Data; Radiology: 2011;260:752-761